sur SARTORIUS STED BIO (EPA:DIM)
Sartorius Stedim Biotech Releases 2025 Universal Registration Document
Sartorius Stedim Biotech SA has announced the availability of its 2025 Universal Registration Document. The document includes key information about the company's business development in 2025 and offers a forecast for 2026. It also features consolidated financial statements for the year ending December 31, 2025. Interested parties can access the document online through the company's investor relations webpage.
Sartorius Stedim Biotech, headquartered in Aubagne, France, is recognized as a major partner to the biopharmaceutical sector. The company provides innovative solutions for the safe, rapid, and sustainable production of biotech medications, including cell and gene therapies. In 2025, the company reported sales revenue of approximately 3 billion euros. Sartorius Stedim Biotech employs over 10,200 people globally and is listed on the Euronext Paris.
R. P.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de SARTORIUS STED BIO